Parsippany, NJ (May 27, 2005) – Data from two clinical studies presented at the American Society of Hypertension's Twentieth Annual Scientific Meeting (ASH 2005) in San Francisco demonstrated that ...

Benicar was developed by Scottish pharmaceutical company Daiichi Sankyo and was used by the U. According to the FDA, primarily In some benicar hct 40 25 mg tablets, patients have been assessed for ...

Parsippany, NJ (May 26, 2004) – New data from two different clinical studies demonstrated that patients with hypertension can achieve more aggressive blood pressure goal rates using antihypertensive ...

Mylan announced the launch of Olmesartan Medoxomil Tablets and Olmesartan Medoxomil and Hydrochlorothiazide Tablets, the first generic versions of Daiichi Sankyo's Benicar and Benicar HCT. Olmesartan ...

[06-11-2010] The U.S. Food and Drug Administration (FDA) is evaluating data from two clinical trials in which patients with type 2 diabetes taking the blood pressure medication, Benicar (olmesartan)* ...

WASHINGTON, DC — The US Food and Drug Administration (FDA) has approved the first generic versions of four drugs that contain the widely used blood pressure-lowering medication olmesartan ...

Even as Daiichi Sankyo makes deep cost cuts to offset revenues lost to generic versions of its blockbuster Benicar, the Japanese drugmaker has agreed to lay out $300 million to settle lawsuits tied to ...

Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB). Olmesartan Medoxomil and Hydrochlorothiazide combines an ARB with a thiazide diuretic. Olmesartan Medoxomil is indicated for the ...